UNASSIGNED: 62 Background: The goal of the Kaiser Permanente (KP) Cancer Care Program is to provide @entity1 -centered, evidence-based, safe care for all KP oncology @entity1 . Multiple processes and information technology tools support KP's clinicians in delivering the best care to our @entity1 . Prior to 2008, chemotherapy ordering and administration across KP was paper-based, and the standardization of chemotherapy regimens was driven by prescribers' preferences. KP Oncologists used more than 1,400 chemotherapy protocols. Pharmacy had varying systems for dosing alerts, and reliable chemotherapy administration data was not available for clinical quality improvement. METHODS: By 2012, all KP regions had implemented the KP HealthConnect Beacon (KPHCB) system, which incorporates chemotherapy ordering, alerting, verifying, dispensing, and administration in ambulatory and inpatient settings. Important outcomes of the KPHCB implementation include: 1) our success in gaining agreements on standardization of chemotherapy protocols across the Program, and 2) implementation of a rapid process for adoption of new scientific evidence. Our approach includes an evaluation of the quality of the relevant scientific literature and an assessment of a particular treatment. The KP multidisciplinary team discusses and integrates the scientific evidence and clinical expertise of KP clinicians into KPHCB chemotherapy protocols. The new evidence-based protocols with supporting literature references are imbedded as a web link at the end of the each protocol and are available to clinicians within days following the publishing of new evidence. RESULTS: An example of a rapid dissemination and adoption of evidence is the 2010 Pfizer's and FDA's announcement that the sale of Mylotarg would be voluntarily discontinued due to a fatal @entity5501 . Within 48 hours, we identified 12 @entity1 who received Mylotarg in 2010, and the treating oncologists were individually contacted and provided with the new information to discuss with @entity1 , as appropriate. CONCLUSIONS: The benefits of KP's rapid adoption of new evidence methodology are reaching over 40,000 @entity5 @entity1 , receiving over 250,000 chemotherapy treatments annually.

Improving quality of XXXX care by rapid adoption of new scientific evidence.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity5501 :: ('MESH:D006504', 'Disease') :: ['liver veno-occlusive disease']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
